As Director of the PET/MRI Program, I am privileged to interact with researchers advancing the state-of-the-art and using PET/MRI in applications spanning preclinical models and human disease. My research focuses on the complementary diagnostic information available with multimodal imaging, either with different quantitative magnetic resonance imaging (MRI) methods or with simultaneous positron emission tomography (PET) and MRI (PET/MRI). I am actively involved in PET/MRI research investigating prostate cancer, glioma, epilepsy, post-stroke cognitive impairment, Alzheimer’s disease, cardiac disease, and musculoskeletal disorders. By helping to advance hybrid PET/MRI technologies, we hope to give new insight into the early biomarkers of disease and improve diagnosis and therapy in patients.
